HUMAN LEUKEMIA ANTIGENS: ISOLATION AND CHARACTERIZATION

白血病和淋巴瘤细胞的免疫学特征 协助调查，旨在提高我们对 人类白血病和淋巴瘤的异质性和病理生理学。我们 进行了白血病和淋巴瘤细胞表面特征的研究 体细胞杂交产生的单抗抗原 技巧。这些抗体已被证明对两者的定义都很有用 白血病和淋巴瘤细胞的异质性和谱系 定义了它们的分化状态。唯一性的识别 通过血清学技术获得的细胞表面抗原可以迅速 多种T、B和髓系细胞白血病的诊断和鉴别 彼此之间的距离。此外，这些独特的细胞表面轮廓具有 允许发展和理解 白血病细胞向正常T、B和髓系细胞分化。 针对白血病细胞的抗体使其迅速发展。 白血病的分类和特征分析方法和 男性中的淋巴瘤。更重要的是，同质性的识别 白血病和淋巴瘤的表型导致这些试剂在 个体恶性肿瘤的诊断和肿瘤的选择 自体移植治疗这些疾病的合适抗体 和不匹配的移植。抗CALLA(J5)的演示是 与大多数非T细胞白血病呈反应，抗Bl抗体呈阳性 大多数B细胞淋巴瘤鼓励使用这些抗体 自体骨髓移植中的骨髓净化。长期的 缓解是通过联合骨髓清理和 激进的化疗。因此，在以下方面取得了相当大的进展 在过去的一年中，利用特定的单抗来治疗 白血病和淋巴瘤的诊断，更重要的是， 特效药对这些疾病的特殊疗法(L8)

The immunologic characterization of leukemic and lymphoma cells has facilitated investigations designed to improve our understanding of the heterogeneity and pathophysiology of human leukemias and lymphomas. We have undertaken studies to characterize leukemic and lymphoma cell surface antigens with monoclonal antibodies produced by somatic cell hybridization techniques. These antibodies have proven useful for the definition of both the heterogeneity and lineage of leukemia and lymphoma cells and in defining their states of differentiation. The identification of unique cell surface antigens by serologic techniques has allowed for the rapid diagnosis and distinction of a variety of T, B, and myeloid cell leukemias from one another. Moreover, these unique cell surface profiles have permitted the development and an understanding of the relationship of the leukemic cell to states of normal T, B, and myeloid cell differentiation. The antibodies to leukemic cells have permitted the development of rapid assays for the classification and characterization of leukemias and lymphomas in man. More importantly, the identification of homogeneous leukemic and lymphoma phenotypes has led to the use of these reagents in both the diagnosis of individual malignancies and the selection of appropriate antibodies for the treatment of these disorders by autologous and mismatched transplantation. The demonstration that anti-CALLA (J5) was reactive with the majority of non-T cell leukemias and anti-Bl was reactive with most B-cell lymphomas has encouraged the use of these antibodies in marrow cleansing in autologous bone marrow transplantation. Long-term remissions have been obtained with a combination of bone marrow cleanup and aggressive chemotherapy. Thus, considerable progress has been made during the past year in the utilization of specific monoclonal antibodies for the diagnosis of leukemias and lymphomas and, more importantly, for the specific therapy of these diseases. (L8)